AUTHOR INDEX

Back, D. J. 251
Ball, S. 251
Benz, C. 155
Branch, R. A. 53
Burchell, B. 261

Cadman, E. 155
Catapano, A. L. 187
Coughtrie, M. W. H. 261

Damon, L. E. 155
Davis, R. A. 221
Dolak, J. A. 139

Glende, E. A., Jr 139
Gram, T. E. 291
Guengerich, F. P. 53

Ji, I. 321, 333
Ji, T. H. 321, 333, 345
Junker, L. H. 221

Karlsson, J.-A. 397
Kreuzer, K. N. 377

Mitchell, S. C. 237

Nishimura, R. 333

O'Boyle, K. M. 1
Okada, Y. 333
Orme, M. L'E. 251

Persson, C. G. A. 397

Recknagel, R. O. 139

Shin, J. 345
Sinensky, M. 221
Sitar, D. S. 363
Stearns, M. E. 299
Sugrue, M. F. 91

Tew, K. D. 299

Waddington, J. L. 1
Waller, R. L. 139
Waring, R. H. 237
Weinshilboum, R. 77
Welling, P. G. 425
Wilkinson, G. R. 53

SUBJECT INDEX

Acyl CoA-cholesterol-acyl transferase (ACAT) in membrane structure 222, 223
Adverse reaction
  estramustine 315, 316
  mephenytoin 53
  methotrexate and 5-FU 167–69
    advanced malignancy 178
  sulfoxidation 246, 247
Airways control
  capsaicin 408
  NANC innervation 397, 398
  neuropeptides 398–401
  peripheral neurotransmitters 397–415
Airways defense
  mechanisms 412–15
  secretions 414, 415
Airways inflammation, NANC nerves 410–12
Alcohol and drug metabolism 365, 366
Antiatherosclerotic drug design 232
Antiglaucoma drugs, pharmacology 91–120
Antitumor effects, 5-FU and methotrexate synergy 162–67
Antiviral action, DNA topoisomerases 377–90
Aqueous humor
  dynamics 91, 92
  elimination 93
  secretion 92

Betaxolol in glaucoma 103, 104
Breast cancer
  combination chemotherapy 174
  5-FU and methotrexate 174–76

Calcitonin gene-related peptide, airways and control 400, 401
Calcium homeostasis, liver cells and carbon tetrachloride 144–49
Cannabinoids in glaucoma 115, 116
Carbonic anhydrase inhibitors in glaucoma 110–13
Carbon tetrachloride toxicity 139–50
  calcium homeostasis, liver cells 144–49
  cytochrome P-450 140
  lipid peroxidation 142–44
  liver cells, indices 139, 140
  oxygen effects 141
S-Carboxymethyl-L-cysteine
  excretion 237, 240
  metabolism 237, 238
  poor metabolizers 239–43
    family studies 241–43
    twin studies 240, 241
  sampling problems 243, 244
  sulfoxidation deficiency 237–47
    age and sex effects 244, 245
    site 245, 246
    variation 238–43
Catechol *O*-methyl transferase (COMT), pharmacogenetics 84, 85

Cholesterol
  catabolism and lipoprotein uptake 226–28
  cellular uptake 224–26
  role in membranes 222, 223
Cholesterol biosynthesis regulation 223, 224
Cholesterol metabolism, pharmacological control 228–31
Cholesterol synthesis regulation 221–33
  inhibition 229–31
Colorectal cancer, methotrexate and 5-FU 169–74
  clinical trials 170, 171
  dose and response 174
  sequencing 173
Crigler–Najjar syndrome, UDP-glucuronosyltransferases 283

Diet *see also* food
  and drug metabolism 363–65, 368
DNA topoisomerases
  adenovirus 387, 388
  antiviral 377–90
  bacteriophage model 383
  eukaryotic virus 384–90
  features 377, 378
  herpesvirus 386, 387
  host utilization 382, 383
  inhibitors 378, 379, 385
  papovavirus 388, 389
  prokaryotic virus 379–84
  retrovirus 389, 390
  vaccinia virus-encoded 384–6
Dopaminergic agonists, selectivity 12, 13
Drug absorption and food 425–38
  clinical implications 437, 438
  decreased 431–33
  delayed 428–31
  increased 433–35
  unaffected 435, 436
Drug metabolism
  human *in vivo* 363–73
  microbial flora 371
  phase I pathways 363–68
  phase II pathways 368–70
  renal function 371
  route 371

Eicosanoids in glaucoma 113–15
Estramustine phosphate
  antimicrotubule effects 299–317
  antimitotic 304
  clinical use 316, 317
  cytoskeletal, effects 315
  cytotoxicity 300
  effects 315, 316
  microtubule-associated proteins 304–10
  structure 299
  target interactions 312–15
  thiol effects and toxicity 310–21

uptake and pharmacokinetics 300–303
X-ray crystallography model 314
Ethinylestradiol
cytochrome P-450 hydroxylation 256–58
metabolic pathways 253, 254
in disease 255, 256
metabolism variation 251–58
genetic control 256
pharmacokinetics 251
plasma levels variation 252, 253
recirculation, hepatic 254, 255

5-Fluorouracil antitumor effects
clinical trials 169–78
metabolic effects 158, 159
methotrexate antagonism 159–62
methotrexate enhancement 155–79
sequence 155
methotrexate synergy 162–65
models 165–67
toxicity 167–69, 178, 179
Follitropin (FSH) 345 *see also* receptors
Food
and drug absorption 425–38
–drug interactions 428
gastrointestinal motility 426, 427
splanchnic blood flow 427
Forskolin in glaucoma 116, 117

Gastric carcinoma, 5-FU and methotrexate 177, 178
Genetic polymorphorism, *S*-mephenytoin hydroxylation 53–73
Gilbert syndrome, UDP-glucuronosyltransferase 282
Glaucoma 91–120
adrenoceptor drugs 94–106
carbonic anhydrase drugs 110–13
cholinergic drugs 108–10
dopamine receptor drugs 106–108
Glucocorticoid antagonists in glaucoma 117, 118
Glucuronidation, metabolic role 261, 262
Gunn rat, genetic lesion 277

Head and neck squamous cell cancer, 5-FU and methotrexate 176, 177
Histidine *N*-methyltransferase, pharmacogenetics 86, 87

4-Ipomeanol
lung electron microscopy 292, 293
pretreatment effects on toxicity 295
pulmonary toxicity 291–96
structure 292

Lecithin cholesterol acyltransferase (LCAT) 222
in membrane structure 222, 223
Levobunolol in glaucoma 104
Low density lipoprotein (LDL) features 187

Macrophage, lipoprotein uptake 231, 232
S-Mephenytoin 4′-hydroxylase
amino acid sequences 65
drugs co-regulated 69–71
hepatic metabolism 62–64
inhibition 68
molecular genetics 64–66
substances metabolized 66–68
Methotrexate
and 5-FU antitumor enhancement 155–79
metabolic effects 156–58
N-Methylation, pharmacogenetics 86, 87
S-Mephenytoin hydroxylation
clinical effects 61, 62
concentration–time curve 58–60
genetic polymorphism 53–73
impaired 54–61
inheritance 57–61
nongenetic factors 71–73
pharmacokinetics 59
Microtubule-associated proteins (MAP)
distribution 306
DU 145 cells 307, 308
estramustine effects 304–10
Microtubules
estramustine effects 299–317
appearance 303
taxol stabilized 310
O-Methylation pharmacogenetics 83–86
S-Methylation pharmacogenetics 77–83
3-Methylfuran, pulmonary microsomes 295
Methyltransferase pharmacogenetics 77–88

Neurotransmitters, peripheral and airways control 397–415
Non-adrenergic, non-cholinergic (NANC) innervation
airways inflammation 410–12
airways tone 402–10
bronchoconstriction 405–10
mediators 406–409
bronchodilation mediators 403–405
capsaicin-sensitive 412

Ocular penetration, drugs 93, 94

Photoaffinity labeling
choriogonadotropin receptor 333–42
follitropin receptor 345–61
Photoaffinity labeling reagents
amino-specific 322, 323
crosslink cleavage 328, 329
crosslinked complex analysis 330
guanido-specific 325
heterobifunctional 321–30
indole-specific 325
photoactivable groups 326, 327
photolysis 327, 328
sulfhydryl 324, 325
Positron emission tomography (PET) dopamine receptors 38–40

Receptors, alpha-adreno, drugs acting 94–97
agonists 94–96
antagonists 96, 97
Receptors, beta-adreno, drugs acting 97–106
agonists 98
antagonists 98–106
Receptors, cholinergic, drugs in glaucoma 108, 110
Receptors, choriogonadotropin
composition 335–38

cross-linked complexes 334, 335
deglycosylated hormone labeling 341, 342
intersubunit disulfides 339–41
labeling sites 339
subunits 338, 339
and labeling 339
Receptor, chylomicron remnant 226
Receptor, dopamine
D_1, D_2 classification 2, 3
drugs affecting 1–40
and glaucoma 106–108
history 1, 2
Receptor, dopamine D_1
ageing 21–23
agonist structures 4–9
selectivity 12–14
antagonists 6
behavioral effects 24–30
biochemical properties 18–20
drug discrimination 28, 29
localization 16–18
molecular characteristics 14–16
neurochemical effects 30–2
neurophysiological effects 32–5
positron emission tomography 38–40
species features 36–38
synthesis 35, 36
up- and down-regulation 23, 24
Receptors, dopamine D_2
ageing 20–23
agonist structures 6–11
selectivity 12–14
antagonists 11, 12
behavioral effects 24–30
biochemical properties 18–20
drug discrimination 28, 29
localization 16–18
molecular characteristics 14–16
neurochemical effects 30–32
neurophysiological effects 32–35
positron emission tomography 38–40
species features 36–38
synthesis 35, 36
up- and down-regulation 23, 24
Receptor, follitropin
characterization 354, 355
components 349, 353
composition 346–49
crosslinked complex composition 349
derivatization 353, 354
disulfide bonds 349–52
labeling site 352, 353
photoaffinity labeling 355–61
specificity 359, 360
proteolytic products 361
Receptor, HDL 226
Receptor, low density lipoprotein (LDL)
acetyl 225
binding domain 193
cholesterol uptake 224, 225
cycle 192
domains 190–93
expression regulation 202, 203
gene 190
ileal by-pass 211, 212
LDL catabolism 203, 204
-mediated lipoprotein uptake 226–28
mutations 196–203
deletions 197
French-Canadian 198
recombination joint 200
Watanabe rabbit 199
pharmacological regulation 205–14
diet 207, 208
drugs 208–10
HMGCoA inhibitors 210
hormones 205, 206
phosphorylation 204
purification 188
scheme 191
sequence 189, 194
bovine 196
rabbit 194
species differences 193–96
tail analysis 201
Receptor, beta-VLDL 225, 226
Resistance, estramustine 315

Sex and drug metabolism 366, 367
Sulfation and drug metabolism 369, 370

Tachykinins
and airways 399, 400
amino acid sequence 400
antagonists 409, 410
catabolism 409
Theophylline release and food 436, 437
Thiol and estramustine toxicity 310–12
Thiol methyltransferase pharmacogenetics 82, 83
Thiopurine methyltransferase pharmacogenetics 78–82
Timolol in glaucoma 98–103

UDP-glucuronosyltransferases 261–84
cell localization 262, 263
characteristics 271, 272
classification and induction 267
deficiencies in man 281–84
DNA cloning 272–74
enzyme family in rat 264–74
functional map 273
genetic deficiencies 274–78
Gunn rats 274–77
genetic regulation 268
isoenzyme properties 272
heterogeneity 273
isoenzymes in man 278–81
cloning 281
purification 280
measurement 263, 264
purification 269–71
structure 265
xenobiotic effects 266–68

Vasoactive intestinal peptide and airways 399

Reproduced with the permission of Pergamon Press Inc., by University Microfilms Inc. Duplication or resale without permission is prohibited.